This is to inform that the company has commenced commercial production effective from 9 March 2020 from DCV-SEZ unit of the company at Chippada Village, Bheemunipatnam Mandal, Visakhapatnam, Divi’s Laboratories said in a statement.
Divis Laboratories’ consolidated net profit fell 7.8% to Rs 359.09 crore on a 2.7% rise in net sales to Rs 1,396.26 crore in Q3 December 2019 over Q3 December 2018.
Divi’s Laboratories is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and intermediates.
Shares of Divis Laboratories fell 3.58% at Rs 2,160. The scrip hovered in the range of Rs 2,141.05 to Rs 2,258 so far.
